Is Psilocybin safe?
Searched over 200M research papers
Research Analysis by Consensus
Consensus Meter
Safety of Psilocybin: A Comprehensive Review
Introduction to Psilocybin Safety
Psilocybin, a naturally occurring psychedelic compound, has garnered significant attention for its potential therapeutic benefits, particularly in treating mental health disorders. However, understanding its safety profile is crucial for its application in clinical settings. This article synthesizes findings from multiple studies to provide a comprehensive overview of psilocybin's safety.
Common Adverse Effects of Psilocybin
Mild and Transient Side Effects
Research indicates that psilocybin is generally well-tolerated when administered in controlled environments. Common adverse effects include headaches, gastrointestinal issues such as nausea, diarrhea, and vomiting, as well as transient increases in heart rate and blood pressure . These side effects are typically mild and resolve within a day.
Psychological Effects
Psilocybin can induce psychological effects such as transient anxiety, paranoia, and confusion, particularly at higher doses. However, these effects are usually manageable and do not lead to long-term issues . The risk of hallucinogenic persisting perception disorder (HPPD) is minimal in clinical settings but may be more relevant in recreational use.
Cardiovascular Safety
Studies have shown that psilocybin can cause modest increases in systolic and diastolic blood pressure. However, these changes are generally not clinically significant and do not lead to serious cardiovascular events. One study reported a case of transient hypertension, which was not associated with anxiety or other somatic symptoms.
Long-Term Safety and Efficacy
Antidepressant Effects
Psilocybin has demonstrated substantial and sustained antidepressant effects, with significant reductions in depressive symptoms observed up to six months post-administration . Long-term follow-up studies have not reported any serious adverse events related to psilocybin use.
Cognitive and Emotional Functioning
In a large randomized controlled trial, psilocybin did not show any detrimental effects on cognitive functioning or emotional processing in healthy participants. The study reported no serious treatment-emergent adverse events, further supporting the compound's safety profile.
Safety in Specific Populations
Patients with Psychiatric Disorders
Psilocybin has been safely administered to patients with various psychiatric conditions, including major depressive disorder and obsessive-compulsive disorder. These studies reported no serious adverse events and highlighted the compound's potential as a therapeutic agent . However, the exclusion of high-risk populations in these studies suggests that further research is needed to confirm its safety across diverse patient groups.
Substance-Dependence Conditions
Preliminary findings suggest that psilocybin can be safely used in patients with substance-dependence conditions, such as alcohol use disorder. The most common adverse effects in these studies were transient and manageable, indicating a favorable safety profile .
Conclusion
The current body of research suggests that psilocybin is generally safe when administered in controlled clinical settings. Common adverse effects are mild and transient, and there is no evidence of serious long-term safety concerns. However, the results should be considered preliminary, and further research is needed to confirm these findings across broader and more diverse populations. As psilocybin continues to be studied, its safety profile will become clearer, potentially paving the way for its use as a therapeutic agent in various mental health and substance-dependence conditions.
Sources and full results
Most relevant research papers on this topic
Psilocybin as an antidepressant strategy - a review of safety aspects
The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation
Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up
Psilocybin-assisted therapy for reducing alcohol intake in patients with alcohol use disorder: protocol for a randomised, double-blinded, placebo-controlled 12-week clinical trial (The QUANTUM Trip Trial)
Safety issues of psilocybin and LSD as potential rapid acting antidepressants and potential challenges
Psilocybin as a New Approach to Treat Depression and Anxiety in the Context of Life-Threatening Diseases—A Systematic Review and Meta-Analysis of Clinical Trials
Trajectory of Antidepressant Effects after Single- or Two-Dose Administration of Psilocybin: A Systematic Review and Multivariate Meta-Analysis
Can psilocybin be safely administered under medical supervision? A systematic review of adverse event reporting in clinical trials
The Tolerability and Safety of Psilocybin in Psychiatric and Substance-Dependence Conditions: A Systematic Review.
Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder.
Try another search
How do we understand and model chemical kinetics?
What is the significance of the theory of everything in physics?
Can psilocybin help with mental health issues?
Amount of exercise experience does not improve motor coordination
What is the role of plate tectonics in shaping the Earth's geology?
E-waste recycling to recover rare earth elements